Cargando…
Toward a Regulatory Qualification of Real-World Mobility Performance Biomarkers in Parkinson’s Patients Using Digital Mobility Outcomes
Wearable inertial sensors can be used to monitor mobility in real-world settings over extended periods. Although these technologies are widely used in human movement research, they have not yet been qualified by drug regulatory agencies for their use in regulatory drug trials. This is because the fi...
Autores principales: | Viceconti, Marco, Hernandez Penna, Sabina, Dartee, Wilhelmus, Mazzà, Claudia, Caulfield, Brian, Becker, Clemens, Maetzler, Walter, Garcia-Aymerich, Judith, Davico, Giorgio, Rochester, Lynn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589106/ https://www.ncbi.nlm.nih.gov/pubmed/33092143 http://dx.doi.org/10.3390/s20205920 |
Ejemplares similares
-
On the use of wearable sensors as mobility biomarkers in the marketing authorization of new drugs: A regulatory perspective
por: Viceconti, Marco, et al.
Publicado: (2022) -
Can Digital Mobility Assessment Enhance the Clinical Assessment of Disease Severity in Parkinson’s Disease?
por: Kirk, Cameron, et al.
Publicado: (2023) -
Mobilizing Parkinson’s Disease: The Future of Exercise
por: Ellis, Terry, et al.
Publicado: (2018) -
Perspectives on statistical strategies for the regulatory biomarker qualification process
por: Hendrix, Suzanne B, et al.
Publicado: (2021) -
Mobility endpoints in marketing authorisation of drugs: what gets the European medicines agency moving?
por: Jaeger, Simon U, et al.
Publicado: (2022)